Compare AAMI & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAMI | PBH |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | N/A | 2004 |
| Metric | AAMI | PBH |
|---|---|---|
| Price | $70.28 | $47.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $58.00 | ★ $75.33 |
| AVG Volume (30 Days) | 506.4K | ★ 653.3K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.91 |
| Revenue | N/A | ★ $975,777,000.00 |
| Revenue This Year | $32.73 | N/A |
| Revenue Next Year | $14.44 | $4.31 |
| P/E Ratio | $23.86 | ★ $11.78 |
| Revenue Growth | N/A | ★ 36.77 |
| 52 Week Low | $33.16 | $42.62 |
| 52 Week High | $85.73 | $81.81 |
| Indicator | AAMI | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 41.65 | 48.46 |
| Support Level | $44.72 | $44.51 |
| Resistance Level | $71.49 | $49.51 |
| Average True Range (ATR) | 3.22 | 1.74 |
| MACD | -1.05 | 0.26 |
| Stochastic Oscillator | 3.76 | 58.33 |
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.